Biomarker phenotyping drives clinical management in axillary sentinel node: A retrospective study on women with primary breast cancer in 2002
Open Access
- 1 July 2020
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 20 (3) , 2469-2476
Abstract
The current study examined if cancer biomarker phenotyping could predict the clinical/pathological status of axillary nodes in women with primary breast cancer. Primary breast cancers from 2002 were analyzed for tumor size, estrogen receptor (ER), progesterone receptor (PgR), Ki‑67MIB expression and Her2/neu amplification. Relationships between the clinical and pathological status of the axilla and the biological subtypes classification were analyzed using univariate, multivariate and regression tree analysis. A total of 65% of women with axillary nodes clinically involved had complete axillary node dissection (ALND) while 705 women with clinically negative axillary underwent sentinel lymph node biopsy (SLNB), 18.5% of the latter had at least one pathologically SLNB involved node. Multivariate analysis revealed that the Luminal A subtype was significantly associated (OR 0.62; P<10‑9) with clinical negative axilla while HER2pos/not Luminal was associated with clinical positivity (OR 1.71; P<0.01). No significant association between biological subtypes and SLNB status was demonstrated. Regression tree analysis revealed that subgroups with significantly different probability of SLNB status were separated according to tumor size and PgR values. In conclusion, the current study demonstrated that biomarker breast cancer phenotyping is significantly associated with clinical status of axillary nodes but not with pathological involvement of nodes at SLNB. Regression tree analysis could represent a valid attempt to individualize some patients subgroups candidate to different surgical axilla approaches.Keywords
This publication has 29 references indexed in Scilit:
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Annals of Oncology, 2013
- Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: entinel node vs bservation after axillary ltraSou )The Breast, 2012
- Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotypeBMC Research Notes, 2012
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast CancerJournal of Clinical Oncology, 2010
- Sentinel Lymph Node Biopsy in Breast CancerAnnals of Surgery, 2010
- The Need for a Quality Control of the Whole Process of Immunohistochemistry Human Epidermal Growth Factor Receptor 2/neu Determination: A United Kingdom National External Quality Assessment Service/Italian Network for Quality Assessment of Tumor Biomarkers Pilot ExperienceJournal of Clinical Oncology, 2007
- Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled studyThe Lancet Oncology, 2006
- Prognostic Relevance of Mitotic Activity in Patients with Node-Negative Breast CancerLaboratory Investigation, 2003
- Clinicopathologic and Technical Factors Associated with the Uptake of Radiocolloid by Sentinel Nodes in Patients with Breast CancerSurgery Today, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001